{
  "source": "PA-Notification-Vtama.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1394-4\nProgram Prior Authorization/Notification\nMedication Vtama® (tapinarof)\nP&T Approval Date 9/2022, 9/2023, 12/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nVtama cream is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque\npsoriasis in adults and the topical treatment of atopic dermatitis in adults and pediatric patients 2\nyears of age and older.\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Vtama will be approved based upon the following criterion:\n(1) Diagnosis of plaque psoriasis\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Vtama will be approved based upon the following criterion:\n(1) Documentation of positive clinical response to therapy\nAuthorization will be issued for 12 months.\nB. Atopic Dermatitis\n1. Initial Authorization\na. Vtama will be approved based upon the following criterion:\n(1) Diagnosis of atopic dermatitis\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Vtama will be approved based upon the following criterion:\n(1) Documentation of positive clinical response to therapy\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits, Medical Necessity, and/or Step Therapy may be in place.\n4. References:\n1. Vtama [package insert]. Long Beach, CA: Dermavant Sciences Inc.; December 2024.\nProgram Prior Authorization/Notifi",
    "ply limits, Medical Necessity, and/or Step Therapy may be in place.\n4. References:\n1. Vtama [package insert]. Long Beach, CA: Dermavant Sciences Inc.; December 2024.\nProgram Prior Authorization/Notification – Vtama® (tapinarof)\nChange Control\n9/2022 New program.\n9/2023 Annual review with no change to clinical criteria.\n12/2024 Annual review. Updated initial authorization to 12 months.\n5/2025 Added coverage criteria for atopic dermatitis. Updated background and\nreference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}